Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Trial updates at ASCO GI 2021

Ghassan Abou-Alfa • 21 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer Liver Cancer Antibodies Ipilimumab Nivolumab
CheckMate 040

Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, discusses the virtual American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium and key updates presented at the meeting, including the long-term results of CheckMate 040, a Phase III study evaluating nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ghassan Abou-Alfa

2:19
Should HCC be treated with locoregional or systemic therapies?
Ghassan Abou-Alfa • 22 Jun 2023
2:32
The role of systemic treatment in early-stage hepatocellular carcinoma
Ghassan Abou-Alfa • 22 Jun 2023
1:53
SCG101: a novel T-cell therapy in advanced hepatitis B-related HCC
Ghassan Abou-Alfa • 22 Jun 2023
3:52
What role does TIGIT inhibition have in treating hepatocellular carcinoma?
Ghassan Abou-Alfa • 22 Jun 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals